What does this research mean for the field?

A mixture of icariin, astragaloside IV, and puerarin (YHG) ameliorates cognitive dysfunction and synaptic impairment in Alzheimer's disease models by inhibiting GSK-3β and enhancing PGC-1α-mediated mitochondrial biogenesis. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to explore the effects of a mixture of icariin, astragaloside IV, and puerarin on synaptic loss and mitochondrial health in Alzheimer's disease.

April 7, 2026Open Access

Icariin, astragaloside IV and puerarin mixture salvages synaptic loss by enhancing mitochondrial biogenesis: A multi-target strategy for Alzheimer’s disease therapy

Key Points

This research aims to explore the effects of a mixture of icariin, astragaloside IV, and puerarin on synaptic loss and mitochondrial health in Alzheimer's disease.
Used APP/PS1 mouse model to assess cognitive dysfunction and synaptic impairment.
Administered YHG mixture to evaluate its effects on mitochondrial biogenesis and oxidative stress.
Analyzed GSK-3β activity and PGC-1α levels to understand mechanisms involved.
YHG treatment improved cognitive function in APP/PS1 mice.
Restoration of synaptic structural integrity was observed post-treatment.
Inhibition of GSK-3β activity and activation of PGC-1α were confirmed, enhancing mitochondrial quality.

Abstract

The YHG ameliorates cognitive dysfunction and attenuates synaptic impairment in APP/PS1 mice. The underlying mechanism may involve the inhibition of GSK-3β activity, which subsequently activates PGC-1α-mediated mitochondrial biogenesis, enhances mitochondrial quality, and mitigates oxidative stress, ultimately leading to the restoration of synaptic structural integrity.

Icariin, astragaloside IV and puerarin mixture salvages synaptic loss by enhancing mitochondrial biogenesis: A multi-target strategy for Alzheimer’s disease therapy

Key Points

Abstract

Cite This Study